Unveiling the Survival Gap: Addressing the Challenges of Acute Lymphoblastic Leukemia in Adolescents
Abstract
Background: Acute Lymphoblastic Leukemia (ALL) remains the most common pediatric cancer, yet survival outcomes vary widely across age groups. In Indonesia, comprehensive data on ALL survival rates are sparse, particularly for adolescents who often fare worse than younger children. The underlying factors contributing to the difference in adolescent survival rates still need to be fully understood. This study aimed to evaluate and compare the survival rates of children and adolescents with ALL treated at Dharmais Cancer Hospital.
Method: We conducted a retrospective cohort analysis of 94 ALL patients, including 37 adolescent patients and 71 patients with B-lineage ALL. All patients with ALL from 2021 to 2023 were identified. Children aged 1–18 years, diagnosed with ALL based on bone marrow results and not yet treated, are included in the study. Patients were stratified by risk stratification (Standard Risk [SR] vs. High Risk [HR]), lineage (B-lineage vs. T-lineage), and age group (children under 10 vs. adolescents 10 years and above). The survival curve was analyzed using the KaplanMeier method, and the log-rank test was used to assess and compare survival across groups.
Results: The overall survival (OS) rate for ALL patients was 49.5%. Adolescents had a significantly lower OS rate of 23.2% compared to children. SR patients exhibited an OS rate of 95.7%, while HR patients had a 33.3%. B-cell lineage had a higher OS rate (59.8%) than T-cell lineage (15.9%). In B-cell ALL, OS was 61.4% in children but only 28.1% in adolescents. Conclusion: The survival rate for adolescents with acute lymphoblastic leukemia (ALL) is significantly lower than that of children, influenced by risk stratification, lineage, and age. Further research is needed to identify these risk factors through genetic and molecular analyses.
Conclusion: The survival rate for adolescents with acute lymphoblastic leukemia (ALL) is significantly lower than that of children, influenced by risk stratification, cell type, and age. Unexplained factors, including lineage differences, remain a challenge in adolescents. Further research into genetic and molecular factors is essential to enhance treatment precision and improve survival rates for ALL patients in Indonesia, especially adolescents.
Keywords: Overall Survival, Leukemia, Adolescent ALL, StratificationKeywords
DOI: 10.33371/ijoc.v19i2.1396
Article Metrics
Abstract View: 460, 
PDF Download: 146
References
Aapro M. CINV: still troubling patients after all these years. Support Care Cancer. 2018 Mar 1;26:5–9.
Dranitsaris G, Molassiotis A, Clemons M, et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapyinduced nausea and vomiting. Ann Oncol. 2017 Jun 1;28(6):1260–7.
Putri RA, Ikawati Z, Rahmawati F, et al. The pattern of adverse drug reactions at a National Cancer Hospital in Indonesia: Analysis of spontaneous reports from healthcare professionals. J Appl Pharm Sci. 2024;
Gravatt LAH, Donohoe KL, Gatesman ML. Nausea and Vomiting. In: DiPiro JT, Yee GC, Haines ST, Nolin TD, Ellingrod VL, Posey LM, editors. DiPiro’s Pharmacotherapy: A Pathophysiologic Approach, 12th Edition [Internet]. New York, NY: McGraw Hill; 2023. Available from: accesspharmacy.mhmedical.com/content.aspx?aid=1206030649
Lau TK, Yip CH, Yeo W. State of the Art Antiemetic Therapy for Cancer Patients. Curr Oncol Rep. 2016 Jan;18(1):2.
Majem M, de Las Peñas R, Virizuela JA, et al. SEOM clinical guideline emesis (2021). Clin Transl Oncol. 2022 Apr;24(4):712-723.
Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27:v119–33.
Ettinger DS, Berger MJ, Agarwal R, et al. NCCN Guidelines Version 1.2024 Antiemesis Continue [Internet]. 2023. Available from: https://www.nccn.
Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020;38(24):2782–97.
Fantry GT. Drugs Used in the Treatment of Gastrointestinal Diseases. In: Vanderah TW, editor. Katzung’s Basic & Clinical Pharmacology, 16th Edition [Internet]. New York, NY: McGraw-Hill; 2024. Available from: accesspharmacy.mhmedical.com/content.aspx?aid=1204147090
Sharkey KA, MacNaughton WK. Gastrointestinal Motility and Water Flux, Emesis, and Biliary and Pancreatic Disease. In: Brunton LL, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 14th Edition [Internet]. New York, NY: McGraw-Hill Education; 2023. Available from: accesspharmacy.mhmedical.com/content.aspx?aid=1193238429
Chu CC, Hsing CH, Shieh JP, Chien CC, Ho CM, Wang JJ. The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting. Eur J Pharmacol. 2014 Jan 5;722:48-54.
Chow R, Herrstedt J, Aapro M, et al. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer. 2021;29:3439–59.
Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Jul 14;375(2):134–42.
Vokes EE. Head and Neck Cancer. In: Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson JL, editors. Harrison’s Principles of Internal Medicine, 21e [Internet]. New York, NY: McGraw-Hill Education; 2022. Available from: accesspharmacy.mhmedical.com/content.aspx?aid=1198035521
Wild CP, Weiderpass E, Stewart BW. World Cancer Report : Cancer research for cancer prevention [Internet]. Lyon (FR): International Agency for Research on Cancer; 2020. Available from: http://publications.iarc.fr/586.
NCCN. NCCN Guidelines Version 2.2024 Head and Neck Cancers. 2023.
Sindhu SK, Bauman JE. Current Concepts in Chemotherapy for Head and Neck Cancer. Oral Maxillofac Surg Clin North Am. 2019 Feb;31(1):145–54.
Galbiatti AL, Padovani-Junior JA, Maníglia JV, et al. Head and neck cancer: causes, prevention and treatment. Braz J Otorhinolaryngol. 2013 Mar-Apr;79(2):239-47.
Mosa ASM, Mosharraf Hossain A, Lavoie BJ, Yoo I. Patient-related risk factors for Chemotherapy-Induced Nausea and Vomiting: A systematic review. Front Pharmacol. 2020 Apr 1;11.
Stinson J, Chan K, Lee J, et al. Managing chemotherapy-induced nausea and vomiting in head and neck cancer patients receiving cisplatin chemotherapy with concurrent radiation. Ann Palliat Med. 2017 Aug 1;6:S13–20.
Rambeau A, Cherifi F, Neviere Z, et al. Platinum-induced nausea and vomiting in patients treated for head and neck cancer. Bull Cancer. 2021;108(5):449–54.
Rapoport BL. Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management. Front Pharmacol. 2017 Jan 30;08.
Lee GW, Oh SY, Kang MH, et al. Treatment of Dexamethasone-Induced Hiccup in Chemotherapy Patients by Methylprednisolone Rotation. Oncologist. 2013 Nov 1;18(11):1229–34.
Go SI, Koo DH, Kim ST, et al. Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial. Oncologist. 2017 Nov;22(11):1354-1361.
Boettger S, Jenewein J, Breitbart W. Haloperidol, risperidone, olanzapine, and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects. Palliat Support Care. 2015 Aug 5;13(4):1079–85.
Choe YM, Kim SY, Choi IG, et al. Olanzapine-induced Concurrent Tardive Dystonia and Tardive Dyskinesia in Schizophrenia with Intellectual Disability: A Case Report. Clin Psychopharmacol Neurosci. 2020 Nov 30;18(4):627–30.
Li Q, Guo D, Yang H, et al. Metabolic Response to Olanzapine in Healthy Chinese Subjects with rs7093146 Polymorphism in Transcription Factor 7‐like 2 Gene ( TCF 7L2 ): A Prospective Study. Basic Clin Pharmacol Toxicol. 2017 Jun 15;120(6):601–9.
Shahrami B, Biglari M, Kaveh-Ahangaran R, et al. Pharmacotherapy Considerations in Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. Eur J Cancer Care. 2023.
Navari RM. Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting. Biomed Res Int. 2015;2015:595894.
Rapoport BL, Herrstedt J, Snow RC, et al. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2023 Dec 18;32(1):36.
Tamura K, Aiba K, Saeki T, et al. Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan. Int J Clin Oncol. 2017 Apr 1;22(2):405–12.
Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol. 2015 Jun;26(6):1081–90.
Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. 2012 Aug;23(8):1986–92.
Chow R, Yin LB, Baqri W, et al. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis. Support Care Cancer. 2023 Aug 3;31(8):505.
Rapoport BL, Chasen MR, Gridelli C, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015 Sep;16(9):1079–89.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Email this article 
